US2252822A - Sulphanilamide solution - Google Patents

Sulphanilamide solution Download PDF

Info

Publication number
US2252822A
US2252822A US267619A US26761939A US2252822A US 2252822 A US2252822 A US 2252822A US 267619 A US267619 A US 267619A US 26761939 A US26761939 A US 26761939A US 2252822 A US2252822 A US 2252822A
Authority
US
United States
Prior art keywords
solution
sulphanilamide
mixture
approximately
proper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US267619A
Inventor
Clarence A Vogenthaler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Donley Evans & Co
Donley-Evans & Co
Original Assignee
Donley Evans & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Donley Evans & Co filed Critical Donley Evans & Co
Priority to US267619A priority Critical patent/US2252822A/en
Application granted granted Critical
Publication of US2252822A publication Critical patent/US2252822A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Definitions

  • the method producing a therapeutic substance in stable solution form which comprises producing a mixture which includes approximately 5% sulphanilamide, approximately 48% glucose, approximately 13% glycerine; said percentages being by weight, and subjecting the mixture so produced to a temperature of at least 75 C. for a period of time of at least thirty minutes to produce a non-toxic solution which is stable at all ordinary temperatures.
  • the method of producing a therapeutic substance in stable solution form which comprises producing a mixture which includes :approxlmately 5% sulphanilamide, approximately 48% glucose, approximately 13% glycerine, said perform of a liquid which is stable at all centages being by weight. and water, and sub- Jecting the mixture so produced to a temperature of at least C. for a period 0! time 0! at least thirty minutes to produce a non-toxic solution which is stable at all ordinary temperatures.
  • a non-toxic therapeutic substance in the form of a liquid which is stable at all ordinary temperatures comprising a mixture that includes approximately 5% sulphanilamide, approximately 48% glucose, and approximately 13% glycerine, said percentages being by weight, said therapeutic substance being produced by subjecting said mixture to a temperature or at least 75 C. for a period of time or at least thirty minutes.
  • a substance in the ordinary temperatures comprising a mixture that includes approximately 5% sulphanilamide, approximately 48% glucose, approximately 13% glycerine, said percentages being by weight, and water, said therapeutic substance being produced by subjecting said mixture to a temperatureof at least 75 C. for a period of time of at least thirty minutes.

Description

, It has further been determined that oral adminisamount of sulphanilamide with a suitable excreted in th free tat As an example of the method followed in pro! Patented Au 1 9, 194i V l 2,252,822
UNITED STATES PATENT OFFICE 2,252,822 v SULPHANILAMIDE SOLUTION Clarence A. Vogenthaler, Ferguson, Mo., assignor to Donley-Evans & Company, St. Louis, Mo., a corporation of Missouri No Drawing. Application Aprllla, 1939',
Serial No. 267,619
4 Claims. (01. lav-es) Within recent years there has come to the much as sulphanilamide must be held in solution attention of the medical profession a chemical of not less than four percent by volume for praccomposition, or dye, known as para-aminobentical purposes and the solubility of sulphanilazenesulphonamide, that has been found to be of mide in cold water and cold alcohol is very much very considerable value in the internal treatment 5v less than this. of streptococcal, meningococcal,gonococcal, and Quite naturally the foregoing facts led to a other infections. For all ordinary purposes this Search or' ome manner or means for administerchemical agent has been termed sulphanilaming sulphanilamide orally that would enable the ide, and it has been observed by medical inhuman body to absorb it more quickly and more vestigators, and physicians who have prescribed completely. The problem so presented has been the composition in their practices, that in the solved by the discovery by me of an improved treatment of the above named and other infecth d n a rdan w th w h su p an lations, sulphanilamide is highly beneficial. mide may be presented in a stable solution of While much is yet to be learned of the actual approximately s ven p r t, by volume, which workings of this chemical agent, it has been deis of S fl c c strength to make 1188 D termined that its value is dependent primarily ticable, and which solution as composed includes on its absorption into the blood stream in sufother chemical agents that are nontoxic and do ficient quantity to reach a high concentration in not produce any chemical ch in h Sulpha short space of time and on maintaining that anilamide itself. a high concentration over the period of treatment. 0 y p v d met od o ves mixing a tration of sulphanilamide produces a higher solvent and subjecting the mixture so pr u d blood concentration than is obtained through its to the proper temperature for the proper period administration by sub-cutaneous or any' other of time. It has been discovered that a solvent method However, prior to this invention sulphthat lends itself admirably to the production of. anilamidc was considered relatively insoluble a sulphanilamide solution in accordanc with (0.8% at 37 C.) and therefore in the use ofthis the teachings of this invention, includes glucose agent heretofore large doses of the drug had to cut Wi h lyc rine. When such a solvent is embe administered frequently to produce the deployed a d mixtllrc 0 s p ilam de and the sired high blood concentration with the result solvent is subjected to the proper heat treatment that in many cases-55% to 60% of the drug was as disclosed herein a stable solution is produced.
Prior to this invention no substance was (11101118 the v d ulphanilamide solution a known which would act as a solvent for sulplimix ure is made up ofapproxima ely 48% anilamide and that could be safely taken into Gluc s pp oximately 1 3% glycerine; approxithe human system, the sulphanilamide marketed mat l sulp a amid and if required to prior to my discovery being in tablet form and give the desired consistency to the solution, an in the form of powder, the tablets containing 0.3 o t f d l d Wa e the percenta gm, and 0.5 gm. of the drug mixed with an ext on d bove\being by weight. The mixture so cipient. It was known heretofore that sulphproduced is slowly he p a y on a Water anilamide was soluble in hot water, hot alcobath. until it s b ought to .a te p tu e of hol and cold acetone, slightly soluble in cold f om C- t 90 C. and the mixture is held water and cold alcohol, practically insoluble in at Such emp e for at least thirty m nut s; hydrochloric acid, and insoluble in ether, benbeing stirred as required to facilitate solution zene, and chloroform. Obviously a hot solvent and to prev formation of u o 1 1 On the could not be used for a sulphanilamide solution surface of the mixture. After the heat is disto be marketed in bottles b cause the sulphntinued a sufll lent quanti f lucose is anilamide would crystallize out of the solution ed to e up for heat loss and the resultant as soon as the solution started to cool. Likewise a mixture is allowed to cool naturally. Obviously acetone, because of its nature, could not be emthe percentages of ingredients mentioned above ployed as a solvent for a composition intended I may, under different conditions, be varied withto taken taken into the human system. Furtherout departing from the spirit of the invention.- more because sulphanilamide is only slightly It has been discovered that the proper applicasoluble in cold water and cold alcohol these on h a 18 mattcr Of v a mportance in mediums could not be employed as solvents inas- 5 producing a sulphanilamide solution in accordance with this invention, it being absolutely essential that the mixture be subjected to the proper temperature for the proper period of time. In the absence of the proper application of heat a stable solution will not be produced even though the mixture is made up of the proper ingredients, such as those specified above, in the proper proportions.
This application is a continuation in part 01 an application for U, patent filed in my name on October 1, 1937, Serial No. 166,831.
I claim:
1. The method producing a therapeutic substance in stable solution form, which comprises producing a mixture which includes approximately 5% sulphanilamide, approximately 48% glucose, approximately 13% glycerine; said percentages being by weight, and subjecting the mixture so produced to a temperature of at least 75 C. for a period of time of at least thirty minutes to produce a non-toxic solution which is stable at all ordinary temperatures.
- 2. The method of producing a therapeutic substance in stable solution form, which comprises producing a mixture which includes :approxlmately 5% sulphanilamide, approximately 48% glucose, approximately 13% glycerine, said perform of a liquid which is stable at all centages being by weight. and water, and sub- Jecting the mixture so produced to a temperature of at least C. for a period 0! time 0! at least thirty minutes to produce a non-toxic solution which is stable at all ordinary temperatures.
3. A non-toxic therapeutic substance in the form of a liquid which is stable at all ordinary temperatures, comprising a mixture that includes approximately 5% sulphanilamide, approximately 48% glucose, and approximately 13% glycerine, said percentages being by weight, said therapeutic substance being produced by subjecting said mixture to a temperature or at least 75 C. for a period of time or at least thirty minutes.
substance in the ordinary temperatures, comprising a mixture that includes approximately 5% sulphanilamide, approximately 48% glucose, approximately 13% glycerine, said percentages being by weight, and water, said therapeutic substance being produced by subjecting said mixture to a temperatureof at least 75 C. for a period of time of at least thirty minutes.
4. A non-toxic therapeutic CLARENCE A. VOGENTHALER.
US267619A 1939-04-13 1939-04-13 Sulphanilamide solution Expired - Lifetime US2252822A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US267619A US2252822A (en) 1939-04-13 1939-04-13 Sulphanilamide solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US267619A US2252822A (en) 1939-04-13 1939-04-13 Sulphanilamide solution

Publications (1)

Publication Number Publication Date
US2252822A true US2252822A (en) 1941-08-19

Family

ID=23019527

Family Applications (1)

Application Number Title Priority Date Filing Date
US267619A Expired - Lifetime US2252822A (en) 1939-04-13 1939-04-13 Sulphanilamide solution

Country Status (1)

Country Link
US (1) US2252822A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2582147A (en) * 1948-04-10 1952-01-08 Norden Lab Inc Sulfonamide composition
US2613170A (en) * 1944-03-02 1952-10-07 Physiological Chemicals Compan Calcium sulfanilamide preparations
US2927056A (en) * 1958-09-23 1960-03-01 Loyola University Sterilizing and antiseptic compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2613170A (en) * 1944-03-02 1952-10-07 Physiological Chemicals Compan Calcium sulfanilamide preparations
US2582147A (en) * 1948-04-10 1952-01-08 Norden Lab Inc Sulfonamide composition
US2927056A (en) * 1958-09-23 1960-03-01 Loyola University Sterilizing and antiseptic compositions

Similar Documents

Publication Publication Date Title
Legrain et al. Infantile acute hemorrhagic edema of the skin: study of ten cases
Kracke et al. THE RELATIONSHIP OF DRUG THERAPY TO AGRANULOCYTOSIS: CLINICAL LECTURE AT ATLANTIC CITY SESSION
US3140978A (en) Pharmaceutical composition containing complex magnesium aluminum silicate
US3069321A (en) Choline salicylate composition and methods of use
US2566200A (en) Oral therapeutic tablets
Bates et al. Correlation between the rate of dissolution and absorption of salicylarnide from tablet and suspension dosage forms
US2252822A (en) Sulphanilamide solution
DE2166355C2 (en) Use of d, 1-sobrerol in balm therapy of the respiratory tract
Sand et al. Pyridium-induced methemoglobinemia: report of a case
US3755592A (en) Method of preparing high concentration calcium ascorbate reaction products and products produced by same
US2147743A (en) Pharmaceutical preparation
US3317377A (en) Sedative-analgesic compositions
US2138546A (en) Therapeutic preparation of colloidal sulphur
US625886A (en) Aisik keeidmann
Dietel et al. Staphylococcus Aureus Meningitis Successfully Treated with Sulfathiazole
US3138529A (en) Tetracycline antibiotic compositions for oral use
US3077438A (en) Stabilization of orally administrable methenamine mandelate sesame oil suspensions containing 12-hydroxy stearic acid triglyceride
JPS59110655A (en) Manufacture of p-butoxyphenylacetylhydroxamic acid
Fairthorne On chloral hydrate
US1741761A (en) Quinine compound and process of making the same
US2414650A (en) Bismuth compounds
DE2256538C2 (en) Probenecid salt of the pivaloyloxymethyl ester of D - (-) - α-aminobenzylpenicillin, its preparation and pharmaceutical compositions containing the same
Gould Atypical mumps
JPH0283323A (en) Stable aqueous solution of riboflavin butyrate
US3519655A (en) Lithium rheinanthrone and lithium rheinanthrone complex salt